Cargando…
Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England
AIMS: People with type 1 diabetes (T1D) face the daily task of implementing self-management strategies to achieve their glycaemic goals. The UK COVID-19 lockdown has had an impact on day-to-day behaviour, which may affect diabetes self-management and outcomes. We assessed whether sensor-based outcom...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567414/ https://www.ncbi.nlm.nih.gov/pubmed/33067723 http://dx.doi.org/10.1007/s00592-020-01614-5 |
_version_ | 1783596321797570560 |
---|---|
author | Prabhu Navis, Joshi Leelarathna, Lalantha Mubita, Womba Urwin, Andrea Rutter, Martin K. Schofield, Jonathan Thabit, Hood |
author_facet | Prabhu Navis, Joshi Leelarathna, Lalantha Mubita, Womba Urwin, Andrea Rutter, Martin K. Schofield, Jonathan Thabit, Hood |
author_sort | Prabhu Navis, Joshi |
collection | PubMed |
description | AIMS: People with type 1 diabetes (T1D) face the daily task of implementing self-management strategies to achieve their glycaemic goals. The UK COVID-19 lockdown has had an impact on day-to-day behaviour, which may affect diabetes self-management and outcomes. We assessed whether sensor-based outcomes pre- and during lockdown periods were different in a cohort of glucose sensor users with T1D. METHODS: Data were collected from Freestyle Libre (FSL) or Dexcom G6 sensor users who remotely shared their data with the diabetes clinic web platform. Sensor metrics according to international consensus were analysed and compared between pre-lockdown period and 2 and 3 weeks into lockdown (periods 1 and 2). RESULTS: Two hundred and sixty-nine T1D patients (baseline HbA1c 57 ± 14 mmol/mol) were identified as FSL (n = 190) or Dexcom G6 (n = 79) users. In patients with sensor use > 70% (N = 223), compared to pre-lockdown period percentage TIR 3.9–10 mM (TIR) significantly increased during period 1 (59.6 ± 18.2 vs. 57.5 ± 17.2%, p = 0.002) and period 2 (59.3 ± 18.3 vs. 57.5 ± 17.2%, p = 0.035). The proportion of patients achieving TIR ≥ 70% increased from 23.3% pre-lockdown to 27.8% in period 1 and 30.5% in period 2. A higher proportion also achieved the recommended time below and above range, and coefficient of variation in periods 1 and 2. Dexcom G6 users had significantly lower % time below range (< 3.9 mM) compared to FSL users during both lockdown periods (period 1: Dexcom G6 vs. FSL: 1.8% vs. 4%; period 2: 1.4% vs. 4%, p < 0.005 for both periods). CONCLUSION: Sensor-based glycaemic outcomes in people with T1D in the current cohort improved during COVID-19 lockdown, which may be associated with positive changes in self-management strategies. Further work is required to evaluate long-term sustainability and support. |
format | Online Article Text |
id | pubmed-7567414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-75674142020-10-19 Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England Prabhu Navis, Joshi Leelarathna, Lalantha Mubita, Womba Urwin, Andrea Rutter, Martin K. Schofield, Jonathan Thabit, Hood Acta Diabetol Original Article AIMS: People with type 1 diabetes (T1D) face the daily task of implementing self-management strategies to achieve their glycaemic goals. The UK COVID-19 lockdown has had an impact on day-to-day behaviour, which may affect diabetes self-management and outcomes. We assessed whether sensor-based outcomes pre- and during lockdown periods were different in a cohort of glucose sensor users with T1D. METHODS: Data were collected from Freestyle Libre (FSL) or Dexcom G6 sensor users who remotely shared their data with the diabetes clinic web platform. Sensor metrics according to international consensus were analysed and compared between pre-lockdown period and 2 and 3 weeks into lockdown (periods 1 and 2). RESULTS: Two hundred and sixty-nine T1D patients (baseline HbA1c 57 ± 14 mmol/mol) were identified as FSL (n = 190) or Dexcom G6 (n = 79) users. In patients with sensor use > 70% (N = 223), compared to pre-lockdown period percentage TIR 3.9–10 mM (TIR) significantly increased during period 1 (59.6 ± 18.2 vs. 57.5 ± 17.2%, p = 0.002) and period 2 (59.3 ± 18.3 vs. 57.5 ± 17.2%, p = 0.035). The proportion of patients achieving TIR ≥ 70% increased from 23.3% pre-lockdown to 27.8% in period 1 and 30.5% in period 2. A higher proportion also achieved the recommended time below and above range, and coefficient of variation in periods 1 and 2. Dexcom G6 users had significantly lower % time below range (< 3.9 mM) compared to FSL users during both lockdown periods (period 1: Dexcom G6 vs. FSL: 1.8% vs. 4%; period 2: 1.4% vs. 4%, p < 0.005 for both periods). CONCLUSION: Sensor-based glycaemic outcomes in people with T1D in the current cohort improved during COVID-19 lockdown, which may be associated with positive changes in self-management strategies. Further work is required to evaluate long-term sustainability and support. Springer Milan 2020-10-16 2021 /pmc/articles/PMC7567414/ /pubmed/33067723 http://dx.doi.org/10.1007/s00592-020-01614-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Prabhu Navis, Joshi Leelarathna, Lalantha Mubita, Womba Urwin, Andrea Rutter, Martin K. Schofield, Jonathan Thabit, Hood Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England |
title | Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England |
title_full | Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England |
title_fullStr | Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England |
title_full_unstemmed | Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England |
title_short | Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England |
title_sort | impact of covid-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in england |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567414/ https://www.ncbi.nlm.nih.gov/pubmed/33067723 http://dx.doi.org/10.1007/s00592-020-01614-5 |
work_keys_str_mv | AT prabhunavisjoshi impactofcovid19lockdownonflashandrealtimeglucosesensoruserswithtype1diabetesinengland AT leelarathnalalantha impactofcovid19lockdownonflashandrealtimeglucosesensoruserswithtype1diabetesinengland AT mubitawomba impactofcovid19lockdownonflashandrealtimeglucosesensoruserswithtype1diabetesinengland AT urwinandrea impactofcovid19lockdownonflashandrealtimeglucosesensoruserswithtype1diabetesinengland AT ruttermartink impactofcovid19lockdownonflashandrealtimeglucosesensoruserswithtype1diabetesinengland AT schofieldjonathan impactofcovid19lockdownonflashandrealtimeglucosesensoruserswithtype1diabetesinengland AT thabithood impactofcovid19lockdownonflashandrealtimeglucosesensoruserswithtype1diabetesinengland |